abstract: OBJECTIVES: Treatment of central and ultra-central @entity2 with stereotactic ablative radiotherapy (SABR) remains controversial due to risks of treatment-related @entity137 compared with @entity1263 . Here we report our institution's experience in treating central and ultra-central @entity2 @entity1 with SABR. MATERIALS AND METHODS: We retrospectively reviewed outcomes in 68 @entity1 with @entity2 , 34 central and 34 peripheral, all treated with SABR consisting of 50Gy in 4-5 fractions. @entity5 centrality was defined per the RTOG 0813 protocol. We defined "ultra-central" @entity5 as those with GTV directly abutting the central airway. RESULTS: Median follow-up time was 18.4months and median overall survival was 38.1 months. Two-year overall survival was similar between ultra-central, central, and peripheral NSCLC (80.0% vs. 63.2% vs. 86.6%, P=0.62), as was 2-year local failure (0% vs. 10.0% vs. 16.3%, P=0.64). @entity137 rates were low and comparable between the three groups, with only two cases of grade 3 @entity137 ( @entity662 ), and one case of grade 4 @entity137 ( @entity55 ) observed. @entity1 with ultra-central @entity5 experienced no symptomatic @entity137 over a median follow-up time of 23.6 months. Dosimetric analysis revealed that RTOG 0813 central airway dose constraints were frequently not achieved in central @entity5 treatment plans, but this did not correlate with increased @entity137 rate. CONCLUSION: @entity1 with central and ultra-central @entity2 treated with SABR (50Gy in 4-5 fractions) experienced few @entity137 and good outcomes, similar to @entity1 with @entity1263 .

title: Stereotactic ablative radiotherapy (SABR) for treatment of central and ultra-central XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity662 :: ('MESH:D002637', 'Disease') :: ['chest wall pain']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'Toxicity', 'toxicities']

entities_list: @entity1263 :: ('MESH:D010524', 'Disease') :: ['peripheral tumors', 'peripheral lung tumors']

entities_list: @entity55 :: ('MESH:D011014', 'Disease') :: ['pneumonitis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'Tumor', 'tumors']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung tumors', 'lung tumor', 'single lung tumors']

answer: @entity2 :: (MESH:D008175,Disease) :: ['lung tumors']


abstract: BACKGROUND/AIMS: Approximately 20% of @entity1 undergoing surgery for @entity31 will retain their rectum. A single-stage proctocolectomy could be an appropriate procedure in @entity1 who are definitely not candidates for a later restorative procedure, but it is generally not advised in acutely ill @entity1 . The aim was to investigate the safety of one-stage proctocolectomy under elective and non-elective circumstances, with specific reference to identifying possible risk factors for @entity260 . METHODS: A retrospective cohort study, including 54 consecutive @entity1 undergoing proctocolectomy for @entity31 . Out of these, 27 (50%) were admitted non-electively. RESULTS: @entity260 were observed in 30 @entity1 (54%). @entity6783 , wound @entity281 , and @entity73 healing were observed in 10 (18.5%), 8 (14.8%), and 10 (18.5%) of the @entity1 , respectively. There was no difference between elective and non-elective cases. Complications were observed more often in @entity1 receiving high-dose corticosteroids (18/26 vs. 12/28; p = 0.06). Impaired perineal wound healing and reoperations were observed more often in the corticosteroid-treated group (8/26 vs. 2/28; p = 0.04 and 12/26 vs. 1/28; p = 0.0003). CONCLUSIONS: Proctocolectomy is equally safe under elective and non-elective situations, but a preoperative treatment with high-dose corticosteroids is associated with an increased risk of complications and reoperations.    2015 S. Karger AG, Basel.

title: Safety of Proctocolectomy for XXXX Under Elective and Non-Elective Circumstances: Preoperative Corticosteroid Treatment Worsens Outcome.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['impaired perineal wound']

entities_list: @entity31 :: ('MESH:D003093', 'Disease') :: ['ulcerative colitis']

entities_list: @entity260 :: ('MESH:D011183', 'Disease') :: ['postoperative complications', 'Postoperative complications']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity6783 :: ('MESH:D013529', 'Disease') :: ['Wound dehiscence']

answer: @entity31 :: (MESH:D003093,Disease) :: ['Ulcerative Colitis']


abstract: OBJECTIVE: @entity20082 is a selective inhibitor of @entity3624 oxidase, which is used to manage @entity5052 in @entity1 with @entity210 . The objective of the study was to compare the pharmacokinetics of two different strength of @entity20082 formulations (80 mg and 40 mg). METHODS: A randomized, single-dose, open-label, two-period, two-sequence crossover study with a 7-day washout period was conducted in 30 healthy male subjects. @entity1 received either reference (1 * 80 mg) or test (2 * 40 mg) formulations during the first period and the alternative formulation during the second period. Plasma samples for the drug analysis were collected up to 24 hours after treatment. RESULTS: All pharmacokinetic parameters were comparable between the two formulations The observed mean Cmax, AUClast, and AUC    values for the reference formulation were 3,670 ng/mL, 12,086 ng*h/mL, and 12,880 ng*h/mL, respectively. Corresponding values for the test formulation were 4,108 ng/mL, 12,689 ng*h/mL, and 13,278 ng*h/mL, respectively. The geometric mean ratios (90% CI) between the two formulations were 1.1273 (1.0286 - 1.2355) for Cmax, 1.054 (1.0115 - 1.0980) for AUClast, and 1.0395 (0.9959 - 1.0851) for AUC   . The changes of serum @entity414 at 24 hours after reference and test formations were comparable (-1.36 mg/dL for reference and -1.37 mg/dL for test; p = 0.892). CONCLUSION: The results of the present study indicated that the reference and test formulations have comparable pharmacokinetics and that these two formulations meet the regulatory criteria for bioequivalence. In addition, the reduction of serum UA levels in the reference formulation was similar to that of the test formulation after a single dose.

title: Comparison of pharmacokinetics and XXXX lowering effect between two different strength febuxostat formulations (80 mg vs. 40 mg) in healthy subjects.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'Participants']

entities_list: @entity3624 :: ('MESH:D019820', 'Chemical') :: ['xanthine']

entities_list: @entity20082 :: ('MESH:C084623', 'Chemical') :: ['Febuxostat', 'febuxostat']

entities_list: @entity5052 :: ('MESH:D033461', 'Disease') :: ['hyperuricemia']

entities_list: @entity414 :: ('MESH:D014527', 'Chemical') :: ['uric acid']

answer: @entity414 :: (MESH:D014527,Chemical) :: ['uric acid']


abstract: Histone H3.3 is a highly conserved histone H3 replacement variant in metazoans and has been implicated in many important biological processes, including cell differentiation and reprogramming. Germline and somatic mutations in H3.3 genomic incorporation pathway components or in H3.3 encoding genes have been associated with @entity1 @entity66 and @entity5 , respectively. However, the role of H3.3 in @entity1 development remains unclear. To address this question, we generated H3.3-null @entity19 models through classical genetic approaches. We found that H3.3 plays an essential role in @entity19 development. Complete depletion of H3.3 leads to @entity851 and early @entity2085 . At the cellular level, @entity19 loss triggers cell cycle suppression and cell death. Surprisingly, H3.3 depletion does not dramatically disrupt gene regulation in the developing embryo. Instead, H3.3 depletion causes dysfunction of heterochromatin structures at telomeres, centromeres, and pericentromeric regions of chromosomes, leading to @entity154 . The resulting karyotypical abnormalities and DNA damage lead to @entity876 pathway activation. In summary, our results reveal that an important function of H3.3 is to support chromosomal heterochromatic structures, thus maintaining genome integrity during @entity1 development.

title: Histone H3.3 maintains genome integrity during XXXX development.

entities_list: @entity1 :: ('9606', 'Species') :: ['mammalian', 'human']

entities_list: @entity154 :: ('MESH:D000013', 'Disease') :: ['mitotic defects']

entities_list: @entity851 :: ('MESH:D006130', 'Disease') :: ['developmental retardation']

entities_list: @entity2085 :: ('MESH:D020964', 'Disease') :: ['embryonic lethality']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['congenital diseases']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancers']

answer: @entity1 :: (9606,Species) :: ['mammalian']


abstract: UNASSIGNED: In the present study, antigens from parthenogenetic females and eggs of Strongyloides venezuelensis, or anti-parthenogenetic-female and anti-egg antigens were used to detect specific IgG and immune complex responses, respectively. Serum samples from experimentally infected immunocompetent and immunosuppressed @entity35 were analysed on days 5, 8, 13 and 21 post- @entity281 (dpi). An enzyme-linked immunosorbent assay (ELISA) was performed using alkaline parasite extract for specific IgG detection, and anti-parthenogenetic-female or anti-egg antigens for immune complex detection. The data were analysed using analysis of variance (ANOVA), followed by a Bonferroni test. When parthenogenetic female or egg extracts were used as antigens, specific IgGs were not detected in either immunocompetent or immunosuppressed rats. When anti-parthenogenetic-female or anti-S. venezuelensis-eggs were used, immune complexes were detected for the duration of the @entity281 in immunosuppressed animals and were only detected between 5 and 13 dpi in immunocompetent animals. The duration of @entity281 was not significantly different between the immunocompetent and immunosuppressed groups when anti-parthenogenetic-female or anti-S. venezuelensis-eggs were used. Parthenogenetic female extracts yielded significant differences between antibody and immune complex responses in immunocompetent @entity35 from 5 to 13 dpi, but only on day 5 dpi in immunosuppressed @entity35 . Exposure to @entity24202 egg extract yielded significant differences in both antibody and immune complex detection between immunocompetent and immunosuppressed @entity35 for the duration of the @entity281 . In conclusion, ELISA using alternative antigens may be a successful strategy for identifying immune complexes in serum samples and diagnosing active @entity13739 , particularly under conditions of immunosuppression.

title: Specific IgG and immune complex responses to parthenogenetic females and eggs of nematode Strongyloides venezuelensis for the diagnosis of immunosuppression in infected XXXX .

entities_list: @entity13739 :: ('MESH:D013322', 'Disease') :: ['strongyloidiasis']

entities_list: @entity24202 :: ('54571', 'Species') :: ['S. venezuelensis']

answer: @entity35 :: (10116,Species) :: ['rats']


abstract: UNASSIGNED: The burden of drug resistance emerges in the wake of chronic and repeated antibiotic use. This underpins the importance of discovering alternatives to current antibiotic regimens. In @entity102 ( @entity102 ), topical therapy such as nasal douches and @entity479 sprays is the mainstay of treatment. However, @entity1244 such as those with @entity794 biofilm infection point to more recalcitrant @entity102 subtypes, focusing research efforts into topical antimicrobial therapies. In the sinuses, both local mucosal and systemic effects must be considered in designing any new topical medication. @entity842 (NO), an endogenous antimicrobial agent, is found at extremely low levels in @entity102 sinuses and high levels in healthy sinuses. As a novel treatment modality, we have designed a liposomal formulation of an NO donor (LFNO) using @entity15230 , as a topical sinus wash in a @entity742 model of @entity794 biofilm rhinosinusitis. Heart rate (HR), blood pressure, mean arterial pressure (MAP), and histologic and ciliary analyses were assessed in the safety component. Efficacy was assessed by quantifying biofilm biomass post-treatment. LFNO-treated @entity742 had lesser @entity32 (P  =  0.02), and comparable ciliary preservation (P  =  0.86) than the control group. A transient increase in HR and decrease in MAP were observed in the LFNO group (P  <  0.05), but this was not accompanied by observable side effects. LFNO @entity742 had significantly lower biofilm biomass vs controls (P  =  0.044). Our findings demonstrate the localized and systemic safety of LFNO in an animal model despite using high NO concentrations, thus warranting further investigation for its possible therapeutic role in @entity102 .

title: An in  vivo safety and efficacy demonstration of a topical liposomal @entity842 donor treatment for XXXX biofilm-associated rhinosinusitis.

entities_list: @entity1244 :: ('MESH:D012852', 'Disease') :: ['bacterial sinusitis']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation']

entities_list: @entity794 :: ('1280', 'Species') :: ['Staphylococcus aureus', 'S. aureus']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic rhinosinusitis', 'CRS']

entities_list: @entity842 :: ('MESH:D009569', 'Chemical') :: ['Nitric oxide']

entities_list: @entity15230 :: ('MESH:C030397', 'Chemical') :: ['isosorbide mononitrate']

answer: @entity794 :: (1280,Species) :: ['Staphylococcus aureus']


abstract: UNASSIGNED: The burden of drug resistance emerges in the wake of chronic and repeated antibiotic use. This underpins the importance of discovering alternatives to current antibiotic regimens. In @entity102 ( @entity102 ), topical therapy such as nasal douches and @entity479 sprays is the mainstay of treatment. However, @entity1244 such as those with @entity794 biofilm infection point to more recalcitrant @entity102 subtypes, focusing research efforts into topical antimicrobial therapies. In the sinuses, both local mucosal and systemic effects must be considered in designing any new topical medication. @entity842 (NO), an endogenous antimicrobial agent, is found at extremely low levels in @entity102 sinuses and high levels in healthy sinuses. As a novel treatment modality, we have designed a liposomal formulation of an NO donor (LFNO) using @entity15230 , as a topical sinus wash in a @entity742 model of @entity794 biofilm rhinosinusitis. Heart rate (HR), blood pressure, mean arterial pressure (MAP), and histologic and ciliary analyses were assessed in the safety component. Efficacy was assessed by quantifying biofilm biomass post-treatment. LFNO-treated @entity742 had lesser @entity32 (P  =  0.02), and comparable ciliary preservation (P  =  0.86) than the control group. A transient increase in HR and decrease in MAP were observed in the LFNO group (P  <  0.05), but this was not accompanied by observable side effects. LFNO @entity742 had significantly lower biofilm biomass vs controls (P  =  0.044). Our findings demonstrate the localized and systemic safety of LFNO in an animal model despite using high NO concentrations, thus warranting further investigation for its possible therapeutic role in @entity102 .

title: An in  vivo safety and efficacy demonstration of a topical liposomal XXXX donor treatment for @entity794 biofilm-associated rhinosinusitis.

answer: @entity842 :: (MESH:D009569,Chemical) :: ['nitric oxide']


abstract: UNASSIGNED: The 21-Gene Recurrence Score Assay has been intensively studied and recommended by major guidelines for treatment decision in early @entity0 . Its impact in adjuvant chemotherapy selection for Chinese population has not been revealed.The prospective part of this study enrolled consecutive node-negative, @entity5282 -positive @entity1 who underwent 21-gene RS testing at Breast Surgery Department of PUMCH (n=134) between May 2012 and August 2013(21-gene RS group). Risk categories were assigned based on the RS and on standard clinicopathologic criteria according to St. Gallen and Adjuvant! Online. The chemotherapy selection and the oncologists' confidence in decision-making before and after RS testing were recorded. The retrospective part of this study compared the chemotherapy decision in the 21-gene RS group and a  control group without RS testing (diagnosed between Jan 2011 and Apr 2012,n=170). A total of 304 @entity1 were included in the analysis (134 21-gene RS group, 170 controls). Based on RS, 97 @entity1 were classified as low risk, 29 @entity1 as intermediate risk, and 8 @entity1 as high risk. @entity5 grade (P=0.002), PR expression (P<0.001) and Ki-67 index (P<0.001) were significantly different between the 3 risk cohorts.Comparing the St. Gallen guidelines and RS, there was a  41% concordance between risk groups. By using Adjuvant! Online, the correlation between the predicted BCSM and RS was nominal (r=0.10). A  total of 29% 21-gene RS group @entity1 changed their treatment decisions after RS testing (P<0.001, 95% CI, 0.18 to 0.49) with 6% (8/134) @entity1 changing to receive chemotherapy besides endocrine therapy and 23% (31/134) changing to reject chemotherapy. After RS testing, more than one half of the oncologists increased their confidence level in treatment recommendation. In the control group, 67.6% (115/170) @entity1 chose chemotherapy plus endocrine therapy. The chemotherapy percentage was much higher than that of 21-gene RS group (30/134, 22%).This is the first study to demonstrate a  reduction in the use of adjuvant chemotherapy in @entity1 with node-negative @entity5282 -positive @entity0 , based on use of the RS. The RS had an impact on the physicians' treatment decision-making.

title: Impact of the 21-Gene Recurrence Score Assay in adjuvant chemotherapy selection for node-negative, @entity5282 -positive XXXX in the Chinese population.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity5282 :: ('3164', 'Gene') :: ['hormone receptor']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

answer: @entity0 :: (MESH:D001943,Disease) :: ['breast cancer']


abstract: UNASSIGNED: The 21-Gene Recurrence Score Assay has been intensively studied and recommended by major guidelines for treatment decision in early @entity0 . Its impact in adjuvant chemotherapy selection for Chinese population has not been revealed.The prospective part of this study enrolled consecutive node-negative, @entity5282 -positive @entity1 who underwent 21-gene RS testing at Breast Surgery Department of PUMCH (n=134) between May 2012 and August 2013(21-gene RS group). Risk categories were assigned based on the RS and on standard clinicopathologic criteria according to St. Gallen and Adjuvant! Online. The chemotherapy selection and the oncologists' confidence in decision-making before and after RS testing were recorded. The retrospective part of this study compared the chemotherapy decision in the 21-gene RS group and a  control group without RS testing (diagnosed between Jan 2011 and Apr 2012,n=170). A total of 304 @entity1 were included in the analysis (134 21-gene RS group, 170 controls). Based on RS, 97 @entity1 were classified as low risk, 29 @entity1 as intermediate risk, and 8 @entity1 as high risk. @entity5 grade (P=0.002), PR expression (P<0.001) and Ki-67 index (P<0.001) were significantly different between the 3 risk cohorts.Comparing the St. Gallen guidelines and RS, there was a  41% concordance between risk groups. By using Adjuvant! Online, the correlation between the predicted BCSM and RS was nominal (r=0.10). A  total of 29% 21-gene RS group @entity1 changed their treatment decisions after RS testing (P<0.001, 95% CI, 0.18 to 0.49) with 6% (8/134) @entity1 changing to receive chemotherapy besides endocrine therapy and 23% (31/134) changing to reject chemotherapy. After RS testing, more than one half of the oncologists increased their confidence level in treatment recommendation. In the control group, 67.6% (115/170) @entity1 chose chemotherapy plus endocrine therapy. The chemotherapy percentage was much higher than that of 21-gene RS group (30/134, 22%).This is the first study to demonstrate a  reduction in the use of adjuvant chemotherapy in @entity1 with node-negative @entity5282 -positive @entity0 , based on use of the RS. The RS had an impact on the physicians' treatment decision-making.

title: Impact of the 21-Gene Recurrence Score Assay in adjuvant chemotherapy selection for node-negative, XXXX -positive @entity0 in the Chinese population.

answer: @entity5282 :: (3164,Gene) :: ['hormone receptor']


abstract: BACKGROUND: (1) To characterize the @entity14062 ( @entity14062 ) of @entity497 individuals with @entity64 and (2) to determine the contribution of @entity14062 to the independence in basic and instrumental activities of daily living (BADL and IADL) and the participation of individuals with @entity64 . @entity14062 is the confidence in one's own ability to perform self-care activities. METHODS: This cross-sectional study included fifty community-dwelling individuals mean (SD) age 59.8 (9.3) years, mean (SD) 3.1 (1.7) years post- @entity64 who were able to walk at least 10 meters. @entity14062 was assessed using the Stroke Self-Efficacy Questionnaire (SSEQ), BADL was assessed by the Functional Independence Measure (FIM) (interview), the IADL questionnaire assessed IADL and the Physical Activity Scale for Individuals with Physical Disabilities (PASIPD) assessed participation. Correlation and regression analyses were performed after controlling for grip strength, executive functions and gait speed, factors known to influence independence in daily living. RESULTS: The mean @entity14062 level was moderate-high (70%). Significant moderate correlations were found between @entity14062 to independence in BADL (r = .596, P < .001), IADL (r = .567, P < .001) and participation (r = .340, P < .005). @entity14062 of our cohort explained 7.4% of the variance of the individual's independence in BADL after controlling for executive functions and gait speed, but did not contribute to their independence in IADL and participation. CONCLUSIONS: Higher @entity14062 of individuals  with @entity64 contributes to more independence in BADL. Additional questionnaires regarding self efficacy for IADL should be developed and investigated.

title: Self-Care Self-Efficacy Correlates with Independence in Basic Activities of Daily Living in Individuals with XXXX .

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke', 'chronic stroke']

entities_list: @entity497 :: ('MESH:D003147', 'Disease') :: ['community dwelling']

entities_list: @entity14062 :: ('MESH:D012652', 'Disease') :: ['self-care self-efficacy', 'SCSE']

answer: @entity64 :: (MESH:D020521,Disease) :: ['Chronic Stroke']


abstract: Thirty-eight cutaneous lesions previously diagnosed as spindle cell @entity957 , " @entity1389 ," or dermal @entity242 are presented. Two @entity1 had two lesions each; thus, there were 36 @entity1 . Cases of @entity320 (including @entity320 ), @entity242 of subcutaneous origin, and " @entity242 " were excluded. On review, the lesions fell into two categories: (1) those with a definite component of invasive @entity957 in addition to @entity242 -like areas (8 cases), and (2) those in which such a squamous component was not identified (30 cases). Cases in the former group were considered proven spindle cell @entity957 , while those in the latter group were designated noncommittally as @entity5 . Almost all @entity1 were white and over 40 years of age. Four @entity5 (from three @entity1 ) arose in areas previously treated with x-ray and all but two (both spindle cell @entity957 ) of the remainder in both categories arose in sun-damaged skin. Prognosis did not differ significantly between the two categories but depended primarily on the depth of invasion. Two of two @entity5 that extended into bone and four of seven that invaded skeletal muscle caused @entity204 ; all of those involving only dermis (24) or dermis and subcutis (five) were successfully extirpated. Origin in an area that had received x-ray was also an unfavorable prognostic indicator; all three @entity1 whose lesions arose in such areas died of @entity5 . This may have been related to depth of invasion because the three fatal @entity5 all invaded muscle. It was concluded that the distinction between spindle cell @entity957 and "atyical fibroxanthoma" is of little prognostic import per se, but rather that prognosis is primarily dependent on the depth of invasion and, perhaps, the type of antecedent irradiation.

title: Spindle cell XXXX and @entity5 of the skin: a comparative study of 38 cases.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity242 :: ('MESH:D012509', 'Disease') :: ['sarcoma', 'neuroid sarcoma']

entities_list: @entity1389 :: ('MESH:C566823', 'Disease') :: ['atypical fibroxanthoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'postradiation sarcoma-like tumors', 'sarcoma-like tumors', 'tumors']

entities_list: @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous carcinomas', 'squamous carcinoma']

entities_list: @entity320 :: ('MESH:D008545', 'Disease') :: ['desmoplastic melanoma', 'spindle cell melanoma']

answer: @entity957 :: (MESH:D002294,Disease) :: ['squamous carcinomas']


abstract: Thirty-eight cutaneous lesions previously diagnosed as spindle cell @entity957 , " @entity1389 ," or dermal @entity242 are presented. Two @entity1 had two lesions each; thus, there were 36 @entity1 . Cases of @entity320 (including @entity320 ), @entity242 of subcutaneous origin, and " @entity242 " were excluded. On review, the lesions fell into two categories: (1) those with a definite component of invasive @entity957 in addition to @entity242 -like areas (8 cases), and (2) those in which such a squamous component was not identified (30 cases). Cases in the former group were considered proven spindle cell @entity957 , while those in the latter group were designated noncommittally as @entity5 . Almost all @entity1 were white and over 40 years of age. Four @entity5 (from three @entity1 ) arose in areas previously treated with x-ray and all but two (both spindle cell @entity957 ) of the remainder in both categories arose in sun-damaged skin. Prognosis did not differ significantly between the two categories but depended primarily on the depth of invasion. Two of two @entity5 that extended into bone and four of seven that invaded skeletal muscle caused @entity204 ; all of those involving only dermis (24) or dermis and subcutis (five) were successfully extirpated. Origin in an area that had received x-ray was also an unfavorable prognostic indicator; all three @entity1 whose lesions arose in such areas died of @entity5 . This may have been related to depth of invasion because the three fatal @entity5 all invaded muscle. It was concluded that the distinction between spindle cell @entity957 and "atyical fibroxanthoma" is of little prognostic import per se, but rather that prognosis is primarily dependent on the depth of invasion and, perhaps, the type of antecedent irradiation.

title: Spindle cell @entity957 and XXXX of the skin: a comparative study of 38 cases.

answer: @entity5 :: (MESH:D009369,Disease) :: ['sarcoma-like tumors']


abstract: OBJECTIVE: Reduced pulmonary function is an important predictor of environment-related @entity358 ; however, evidence of an association between exposures to various metals from all possible routes and altered pulmonary function is limited. We aimed to investigate the association of various metals in urine with pulmonary function, @entity358 ( @entity358 ) and @entity3885 ( @entity3885 ) risks in the general Chinese population. DESIGN: A cross-sectional investigation in the Wuhan cohort population. SETTING: A heavily polluted Chinese city. @entity1 : A total of 2460 community-living Chinese adults from the Wuhan cohort were included in our analysis. MAIN OUTCOME MEASURES: Spirometric parameters (FVC, forced vital capacity; FEV1, forced expiratory volumes in 1   s; FEV1/FVC ratio), @entity358 and @entity3885 . RESULTS: The dose-response associations of pulmonary function, and @entity358 and @entity3885 , with 23 urinary metals were assessed using regression analysis after adjusting for potential confounders. The false discovery rate (FDR) method was used to correct for multiple hypothesis tests. Our results indicated that there were positive dose-response associations of urinary iron with FEV1 and FEV1/FVC ratio, vanadium with FEV1, and copper and selenium with FEV1/FVC ratio, while a negative dose-response association was observed between urinary lead and FEV1/FVC ratio (all p<0.05). After additional adjusting for multiple comparisons, only iron was dose dependently related to FEV1/FVC ratio (FDR adjusted p<0.05). The dose-response association of iron and lead, with decreased and increased @entity1030 risk, respectively, was also observed (both p<0.05). Additionally, we found significant association of urinary zinc with @entity358 and interaction effects of smoking status with lead on FEV1/FVC, and with cadmium on FVC and FEV1. CONCLUSIONS: These results suggest that multiple urinary metals are associated with altered pulmonary function, and @entity358 and @entity3885 prevalences.

title: The dose-response association of urinary metals with altered pulmonary function and risks of XXXX : a population-based study in China.

entities_list: @entity1 :: ('9606', 'Species') :: ['PARTICIPANTS']

entities_list: @entity358 :: ('MESH:D008171', 'Disease') :: ['restrictive lung disease', 'RLD', 'pulmonary diseases']

entities_list: @entity3885 :: ('MESH:D008173', 'Disease') :: ['obstructive lung disease', 'OLD']

entities_list: @entity1030 :: ('MESH:D029424', 'Disease') :: ['chronic obstructive pulmonary disease']

answer: @entity3885 :: (MESH:D008173,Disease) :: ['restrictive and obstructive lung diseases']


abstract: UNASSIGNED: Immunity to non-cerebral severe @entity311 is estimated to occur within 1-2 infections in areas of endemic transmission for @entity3964 . Yet, nearly 20% of infected @entity1 die annually as a result of severe @entity311 . Multiple risk factors are postulated to exacerbate @entity66 , one being @entity325 with other pathogens. @entity1 living in Sub-Saharan Africa are seropositive for @entity9653 ) by the age of 6 months. This timing overlaps with the waning of protective maternal antibodies and susceptibility to primary @entity3964 @entity281 . However, the impact of acute @entity2025 on the generation of anti-malarial immunity is unknown. Using well established @entity19 models of @entity281 , we show here that acute, but not latent @entity21525 (MHV68) @entity281 suppresses the anti-malarial humoral response to a secondary @entity281 . Importantly, this resulted in the transformation of a non-lethal @entity501 XNL @entity281 into a lethal one; an outcome that is correlated with a defect in the maintenance of germinal center B cells and T follicular helper (Tfh) cells in the spleen. Furthermore, we have identified the MHV68 M2 protein as an important virus encoded protein that can: (i) suppress anti-MHV68 humoral responses during acute MHV68 @entity281 ; and (ii) plays a critical role in the observed suppression of anti-malarial humoral responses in the setting of @entity325 . Notably, @entity325 with an M2-null mutant MHV68 eliminates lethality of @entity501 XNL. Collectively, our data demonstrates that an acute gammaherpesvirus @entity281 can negatively impact the development of an anti-malarial immune response. This suggests that @entity697 with EBV should be investigated as a risk factor for non-cerebral severe @entity311 in young @entity1 living in areas endemic for @entity3964 transmission.

title: Gammaherpesvirus XXXX with @entity311 Suppresses Anti-parasitic Humoral Immunity.

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'Children']

entities_list: @entity697 :: ('MESH:D000208', 'Disease') :: ['acute infection']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['malarial disease']

entities_list: @entity2025 :: ('MESH:D020031', 'Disease') :: ['EBV infection']

entities_list: @entity21525 :: ('33708', 'Species') :: ['murine gammaherpesvirus 68']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection', 'malaria infection']

entities_list: @entity9653 :: ('10376', 'Species') :: ['Epstein Barr Virus (EBV']

entities_list: @entity325 :: ('MESH:D060085', 'Disease') :: ['co-infections', 'co-infection']

entities_list: @entity3964 :: ('5833', 'Species') :: ['Plasmodium falciparum', 'Plasmodium']

answer: @entity325 :: (MESH:D060085,Disease) :: ['Co-infection']


abstract: UNASSIGNED: Immunity to non-cerebral severe @entity311 is estimated to occur within 1-2 infections in areas of endemic transmission for @entity3964 . Yet, nearly 20% of infected @entity1 die annually as a result of severe @entity311 . Multiple risk factors are postulated to exacerbate @entity66 , one being @entity325 with other pathogens. @entity1 living in Sub-Saharan Africa are seropositive for @entity9653 ) by the age of 6 months. This timing overlaps with the waning of protective maternal antibodies and susceptibility to primary @entity3964 @entity281 . However, the impact of acute @entity2025 on the generation of anti-malarial immunity is unknown. Using well established @entity19 models of @entity281 , we show here that acute, but not latent @entity21525 (MHV68) @entity281 suppresses the anti-malarial humoral response to a secondary @entity281 . Importantly, this resulted in the transformation of a non-lethal @entity501 XNL @entity281 into a lethal one; an outcome that is correlated with a defect in the maintenance of germinal center B cells and T follicular helper (Tfh) cells in the spleen. Furthermore, we have identified the MHV68 M2 protein as an important virus encoded protein that can: (i) suppress anti-MHV68 humoral responses during acute MHV68 @entity281 ; and (ii) plays a critical role in the observed suppression of anti-malarial humoral responses in the setting of @entity325 . Notably, @entity325 with an M2-null mutant MHV68 eliminates lethality of @entity501 XNL. Collectively, our data demonstrates that an acute gammaherpesvirus @entity281 can negatively impact the development of an anti-malarial immune response. This suggests that @entity697 with EBV should be investigated as a risk factor for non-cerebral severe @entity311 in young @entity1 living in areas endemic for @entity3964 transmission.

title: Gammaherpesvirus @entity325 with XXXX Suppresses Anti-parasitic Humoral Immunity.

answer: @entity311 :: (MESH:D008288,Disease) :: ['Malaria']


abstract: UNASSIGNED: @entity2759 ( @entity2759 ) is a devastating complication of aortic operations. Neuromonitoring using @entity1957 ( @entity1957 ) is a sensitive modality to detect @entity2759 in @entity1 . We describe a leporine @entity2759 model using @entity1957 to test pharmaceutical therapeutics and other neuroprotective adjuncts. In 80 @entity95 , methods to obtain @entity1957 in normotensive and @entity63 @entity95 were developed. The effects of @entity5161 , @entity1875 , @entity386 , and @entity551 on lower extremity @entity1957 were studied. Lower extremity @entity1957 disappear upon @entity2759 induction in 78 of 78 (100  %) @entity95 . Prior to @entity2759 induction and during @entity2749 , lower extremity @entity1957 were lost in all (100  %) and upper extremity @entity1957 in one (25  %). @entity5161 was used in four experiments, with loss of lower extremity @entity1957 in all four (100  %) and loss of upper extremity @entity1957 in zero. With @entity1875 upper extremity, @entity1957 were obtainable in 80 of 80 @entity95 (100  %) and lower extremity @entity1957 in 78 of 80 @entity95 (97.5  %) prior to @entity2759 induction. The presence of these lower extremity @entity1957 prior to @entity2759 induction was not correlated with @entity551 . Disappearance of @entity1957 occurred in all 45 @entity95 with @entity86 . @entity1957 in the leporine model correlate closely with @entity451 . @entity1957 are influenced by inhaled anesthetics and @entity386 but not by @entity551 alone. @entity1875 anesthesia provides reliable @entity1957 . This study provides the basis for a reproducible model of @entity2759 to be used for novel therapeutic drug development.

title: Methodology of Motor Evoked Potentials in a XXXX Model.

entities_list: @entity2749 :: ('MESH:C580065', 'Disease') :: ['apneic episodes']

entities_list: @entity451 :: ('MESH:C536857', 'Disease') :: ['paraplegia']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic']

entities_list: @entity1957 :: ('MESH:D019957', 'Disease') :: ['MEPs', 'motor evoked potentials']

entities_list: @entity2759 :: ('MESH:D020760', 'Disease') :: ['SCI', 'Spinal cord ischemia']

entities_list: @entity1875 :: ('MESH:D015742', 'Chemical') :: ['propofol', 'Propofol']

entities_list: @entity86 :: ('MESH:D019106', 'Disease') :: ['postoperative lower extremity impairment']

entities_list: @entity5161 :: ('MESH:D007530', 'Chemical') :: ['Isoflurane', 'isoflurane']

entities_list: @entity551 :: ('MESH:D007022', 'Disease') :: ['systolic or diastolic blood pressure', 'hypotension']

answer: @entity95 :: (9986,Species) :: ['Rabbit']


abstract: PURPOSE: To assess the impact of increasing dose on @entity1349 ( @entity1349 ) for @entity263 @entity1 . METHODS: Treatment data were obtained on more than 20,000 @entity1 in the National Oncology Data Alliance  , a proprietary database of merged @entity5 registries, who were treated for @entity263 with definitive radiotherapy between 1995 and 2006. Eligible @entity1 had complete data on total dose, T stage, use and timing of @entity342 deprivation therapy (ADT), and treatment start date (n   =   20,028). @entity1 with prior @entity5 were excluded. RESULTS: On multivariate analysis, dose, T stage, grade, marital status, age, and neoadjuvant ADT were significant predictors of @entity1349 . Hazard ratios for @entity1349 declined monotonically with increasing dose, reaching 0.63 (95  % Confidence Interval 0.53-0.76) at >= 80  Gy. On subset analysis, neoadjuvant ADT significantly improved @entity1349 in high risk @entity1 but was not significant in lower risk @entity1 . The dose response was maintained across all risk groups. Medical comorbidities were balanced across all dose strata and sensitivity analysis demonstrated that other prognostic factors were unlikely to explain the observed dose response. CONCLUSIONS: This study suggests that increasing dose significantly improves @entity1349 in @entity263 @entity1 treated with radiotherapy.

title: The impact of increasing dose on @entity1349 in XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity263 :: ('MESH:D011471', 'Disease') :: ['prostate cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'malignancies']

entities_list: @entity342 :: ('CHEBI:50113', 'Chemical') :: ['androgen']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity263 :: (MESH:D011471,Disease) :: ['prostate cancer']


abstract: PURPOSE: To assess the impact of increasing dose on @entity1349 ( @entity1349 ) for @entity263 @entity1 . METHODS: Treatment data were obtained on more than 20,000 @entity1 in the National Oncology Data Alliance  , a proprietary database of merged @entity5 registries, who were treated for @entity263 with definitive radiotherapy between 1995 and 2006. Eligible @entity1 had complete data on total dose, T stage, use and timing of @entity342 deprivation therapy (ADT), and treatment start date (n   =   20,028). @entity1 with prior @entity5 were excluded. RESULTS: On multivariate analysis, dose, T stage, grade, marital status, age, and neoadjuvant ADT were significant predictors of @entity1349 . Hazard ratios for @entity1349 declined monotonically with increasing dose, reaching 0.63 (95  % Confidence Interval 0.53-0.76) at >= 80  Gy. On subset analysis, neoadjuvant ADT significantly improved @entity1349 in high risk @entity1 but was not significant in lower risk @entity1 . The dose response was maintained across all risk groups. Medical comorbidities were balanced across all dose strata and sensitivity analysis demonstrated that other prognostic factors were unlikely to explain the observed dose response. CONCLUSIONS: This study suggests that increasing dose significantly improves @entity1349 in @entity263 @entity1 treated with radiotherapy.

title: The impact of increasing dose on XXXX in @entity263 .

answer: @entity1349 :: (MESH:D011475,Disease) :: ['overall survival']


abstract: AIM: To describe the prevalence and characteristics of @entity239 ( @entity239 ) in @entity1 with underlying @entity627 , and to compare it by three different measures. METHODS: We studied 546 @entity1 with chronic @entity627 who attended our rheumatology clinic. If @entity1 answered all of a screening questionnaire with yes, then we considered @entity1 to be having @entity158 as assessed by the @entity239 impact questionnaire (FIQ), @entity158 index (WPI), and @entity146 ( @entity146 ). A physician administered the tender point (TP) exam and clinician's judgment of @entity239 . We collected demographics, clinical and laboratory features. RESULTS: One hundred and sixty-four (30.0%) @entity1 among 546 cases had a further exam. The male-to-female count was 25  :  139. The mean age was 49.7  years, disease duration 3.7  years, TP counts 4.2, FIQ score 47.0 and WPI with @entity146 score was 11.1. We classified 17 @entity1 (10.4%) with concomitant @entity239 with @entity158 by tender point exam, 56 @entity1 (34.2%) by WPI with @entity146 , and 36 @entity1 (22.0%) by a clinician's judgment. A total of 70.6% (n  =  12) of those classified as @entity239 by 1990 American College of Rheumatology (ACR) criteria wee categorized as @entity239 by clinician's judgment, while 33.3% by clinician's judgment were classified by 1990 ACR criteria. CONCLUSIONS: We found a 10.4~34.2% prevalence of concomitant @entity239 in the @entity1 with chronic @entity158 . The 1990 ACR criteria were the most restrictive except for @entity1252 . Although The 2010 ACR criteria had a wide spectrum, it can be used for @entity239 diagnosis even in the @entity1 with underlying @entity627 .

title: XXXX with chronic @entity627 in South Korea: a comparison of clinical and American College of Rheumatology criteria.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity239 :: ('MESH:D005356', 'Disease') :: ['fibromyalgia', 'FM']

entities_list: @entity627 :: ('MESH:D012216', 'Disease') :: ['rheumatic diseases', 'rheumatic disease']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['symptom severity', 'SS']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['widespread pain']

answer: @entity239 :: (MESH:D005356,Disease) :: ['Fibromyalgia']


abstract: AIM: To describe the prevalence and characteristics of @entity239 ( @entity239 ) in @entity1 with underlying @entity627 , and to compare it by three different measures. METHODS: We studied 546 @entity1 with chronic @entity627 who attended our rheumatology clinic. If @entity1 answered all of a screening questionnaire with yes, then we considered @entity1 to be having @entity158 as assessed by the @entity239 impact questionnaire (FIQ), @entity158 index (WPI), and @entity146 ( @entity146 ). A physician administered the tender point (TP) exam and clinician's judgment of @entity239 . We collected demographics, clinical and laboratory features. RESULTS: One hundred and sixty-four (30.0%) @entity1 among 546 cases had a further exam. The male-to-female count was 25  :  139. The mean age was 49.7  years, disease duration 3.7  years, TP counts 4.2, FIQ score 47.0 and WPI with @entity146 score was 11.1. We classified 17 @entity1 (10.4%) with concomitant @entity239 with @entity158 by tender point exam, 56 @entity1 (34.2%) by WPI with @entity146 , and 36 @entity1 (22.0%) by a clinician's judgment. A total of 70.6% (n  =  12) of those classified as @entity239 by 1990 American College of Rheumatology (ACR) criteria wee categorized as @entity239 by clinician's judgment, while 33.3% by clinician's judgment were classified by 1990 ACR criteria. CONCLUSIONS: We found a 10.4~34.2% prevalence of concomitant @entity239 in the @entity1 with chronic @entity158 . The 1990 ACR criteria were the most restrictive except for @entity1252 . Although The 2010 ACR criteria had a wide spectrum, it can be used for @entity239 diagnosis even in the @entity1 with underlying @entity627 .

title: @entity239 with chronic XXXX in South Korea: a comparison of clinical and American College of Rheumatology criteria.

answer: @entity627 :: (MESH:D012216,Disease) :: ['rheumatic diseases']


abstract: Electrophysiologic studies of His' bundle were done on 32 consecutive @entity1 with symptomatic @entity340 . Nineteen had pure @entity337 and 13 had @entity472 , four with significant regurgitation. Fifteen of the former had atrioventricular (AV) and/or intraventricular (IV) @entity616 . In those with @entity472 , eight had @entity616 , all intraventricular but one. Twelve of the 13 with @entity472 had radiographically indentifiable @entity7874 ; all four with a peak systolic gradient greater than 80 mm Hg had @entity1757 . Of the 32 @entity1 , six had A-H prolongation and in all the predominant lesion was @entity337 (one with moderate @entity850 ). There was no difference in age, clinical @entity712 , @entity453 , or prolonged H-V interval. However, PR prolongation (P = .01) and decreased ejection fraction (P = .02) was significantly increased in the former group. @entity1 with @entity337 had longer A-H and H-V intervals (NS), induced @entity616 at lower heart rates (P = .01), and higher A-V node effective (P = .001) and functional (P = .01) refractory periods. In summary, @entity1 with @entity340 have a high incidence of atrioventricular and intraventricular conduction disease.

title: Atrioventricular and intraventricular conduction disturbances in XXXX .

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['congestive heart failure']

entities_list: @entity850 :: ('MESH:D003251', 'Disease') :: ['stenosis']

entities_list: @entity1757 :: ('MESH:D006345', 'Disease') :: ['IV conduction defects']

entities_list: @entity472 :: ('MESH:D001024', 'Disease') :: ['aortic stenosis']

entities_list: @entity7874 :: ('MESH:C562942', 'Disease') :: ['valve calcification']

entities_list: @entity337 :: ('MESH:D001022', 'Disease') :: ['aortic regurgitation']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease']

entities_list: @entity340 :: ('MESH:D006349', 'Disease') :: ['aortic valvular disease']

entities_list: @entity616 :: ('MESH:D006327', 'Disease') :: ['A-V block', 'conduction abnormalities']

answer: @entity340 :: (MESH:D006349,Disease) :: ['aortic valvular disease']


abstract: BACKGROUND: We assessed the effectiveness of perioperative MAGIC-style chemotherapy in our series focused on the @entity5 regression grade and survival rate. METHODS: We conducted a retrospective study of 53 @entity1 following a perioperative regimen of epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/X). Forty-four (83  %) @entity5 were located in the stomach and 9 (17  %) were located at the esophagogastric junction. Perioperative chemotherapy completion, resection, TNM staging, the @entity5 regression grade (Becker's classification) and survival were analyzed. RESULTS: Forty-five @entity1 (85  %) completed the 3 preoperative cycles. R0 resection was achieved in 42 (79  %) @entity1 . Thirty-five (66  %) @entity1 completed the 3 postoperative cycles. Nine @entity189 (17  %) were considered major responders after preoperative chemotherapy. With multivariate analysis, only completion of perioperative chemotherapy (HR: 0.25; 95%CI: 0.08 - 0.79; p   =   0.019) was identified as an independent prognostic factor for disease-specific survival. However, the protective effect of perioperative therapy was lost in @entity1 with ypT3-4 and more than 4 positive lymph nodes (HR: 1.16; 95%CI: 1.02 - 1.32; p   =   0.029). The @entity5 regression grade (major vs minor responders) was at the limit of significance only with univariate analysis. The 5-year overall and disease-specific survival rates were 18  % and 22  % respectively. CONCLUSIONS: The percentage of major responder @entity5 after preoperative chemotherapy was low. Completion of perioperative ECF/X chemotherapy may benefit @entity1 with @entity356 that do not invade the subserosa with few positive lymph nodes.

title: Tumor regression and survival after perioperative MAGIC-style chemotherapy in XXXX and gastroesophageal junction.

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'neoplasias', 'tumors']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity356 :: ('MESH:D013274', 'Disease') :: ['gastric carcinomas']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinomas']

answer: @entity189 :: (MESH:D002277,Disease) :: ['carcinoma of the stomach']


abstract: BACKGROUND: Urothelial @entity150 is a highly heterogeneous disease. @entity5 cell lines are useful tools for its study. This is a comprehensive genomic characterization of 40 urothelial @entity150 (UBC) cell lines including information on origin, mutation status of genes implicated in @entity150 ( @entity2557 , @entity10160 , @entity876 , and RAS), copy number alterations assessed using high density SNP arrays, @entity8882 ( @entity8882 ) events, and gene expression. RESULTS: Based on gene mutation patterns and genomic changes we identify lines representative of the @entity2557 -driven @entity5 pathway and of the @entity876 /RB @entity5 suppressor-driven pathway. High-density array copy number analysis identified significant focal gains (1q32, 5p13.1-12, 7q11, and 7q33) and losses (i.e. 6p22.1) in regions altered in @entity5 but not previously described as affected in bladder cell lines. We also identify new evidence for frequent regions of @entity8882 , often coinciding with regions reported to be lost in @entity5 . Previously undescribed chromosome X losses found in UBC lines also point to potential @entity5 suppressor genes. Cell lines representative of the @entity2557 -driven pathway showed a lower number of @entity8882 events. CONCLUSIONS: Overall, there is a predominance of more @entity146 subtypes among the cell lines. We provide a cell line classification that establishes their relatedness to the major molecularly-defined @entity150 subtypes. The compiled information should serve as a useful reference to the @entity150 research community and should help to select cell lines appropriate for the functional analysis of @entity150 genes, for example those being identified through massive parallel sequencing.

title: The UBC-40 Urothelial Bladder XXXX cell line index: a genomic resource for functional studies.

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['aggressive tumor']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'tumors', 'Cancer']

entities_list: @entity150 :: ('MESH:D001749', 'Disease') :: ['bladder tumor', 'bladder carcinoma', 'bladder cancer']

entities_list: @entity8882 :: ('MESH:D024182', 'Disease') :: ['UPD', 'uniparental disomy']

answer: @entity5 :: (MESH:D009369,Disease) :: ['Cancer']


abstract: Based on the experience of a Short Term Scientific Mission (STSM) promoted by COST Net and developed in CIES/ISCTE-IUL (Portugal), this paper presents a reflection about the implementation of @entity497 ( @entity497 ) in the healthcare sector in Israel and Portugal. Specifically, we focus on the impacts of @entity497 or eHealth on @entity1 empowerment, as perceived by doctors and managers in order to better comprehend the role of national policy and explore the options for building a national strategy regarding @entity497 in healthcare. The experience of the Portuguese healthcare system was selected and compared to the results found in a similar research in Israel. Methodologically, in-depth interviews with the Ministry of Health, the private sector, @entity1 associations and researches were used to collect data. Purposeful sampling was used to select respondents, and secondary sources were used for triangulation. The findings of the research work show that the increased deployment of @entity497 has furthered @entity1 empowerment (1). From the doctors' perspective, while @entity497 has provided more information in the long-run, changes of these magnitudes were not easy in the beginning. These findings were similar in both countries. The work concludes that @entity497 tools were successfully implemented and the general perception is that they have been beneficial. The work provides information in order to understand and improve @entity497 services. Additionally, the results suggest alternatives for future investments in these technologies.

title: The Impact of eHealth and mHealth on doctor behavior and XXXX involvement: an Israeli and Portuguese comparative approach.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity497 :: ('MESH:D003147', 'Disease') :: ['Information _ Communication Technologies', 'ICT']

answer: @entity1 :: (9606,Species) :: ['patient']


abstract: OBJECTIVES: The aim of our study was to determine the diagnostic value of a novel image analysis method called parametric response mapping (PRM) for prediction of intrahepatic recurrence of @entity157 ( @entity157 ) treated with conventional transcatheter arterial chemoembolization (TACE). METHODS: This retrospective study was approved by the IRB. We recruited 55 @entity157 @entity1 who achieved complete remission (CR) after TACE and received longitudinal multiphasic liver computed tomography (CT). The @entity1 fell into two groups: the recurrent @entity5 group (n   =   29) and the non-recurrent @entity5 group (n   =   26). We applied the PRM analysis to see if this technique could distinguish between the two groups. The results of the PRM analysis were incorporated into a prediction algorithm. We retrospectively removed data from the last time point and attempted to predict the response to therapy of the removed data. RESULTS: The PRM analysis was able to distinguish between the non-recurrent and recurrent groups successfully. The prediction algorithm detected response to therapy with an area under the curve (AUC) of 0.76, while the manual approach had AUC 0.64. CONCLUSIONS: Adopting PRM analysis can potentially distinguish between recurrent and non-recurrent HCCs and allow for prediction of response to therapy after TACE. KEY POINTS:     Parametric response mapping (PRM) could help assess @entity1 with recurrent HCCs after TACE.     Parametric response mapping could direct @entity1 to individualized therapy.     Longitudinal CT images were analyzed with advanced image analysis method.

title: Parametric response mapping of dynamic CT for predicting intrahepatic recurrence of XXXX after conventional transcatheter arterial chemoembolization.

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinoma']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumour']

answer: @entity157 :: (MESH:D006528,Disease) :: ['hepatocellular carcinoma']


abstract: UNASSIGNED: @entity392 is an incapacitating condition commonly affecting cochlear implant (CI) candidates. The aim of this clinical study is to assess the long-term effects of CI treatment in @entity1 with severe-to-profound, sensorineural, @entity393 ( @entity393 ) and incapacitating @entity392 . We performed a prospective Cochlear    company-sponsored multicentre study in five Spanish centres. Sixteen @entity1 with @entity393 and incapacitating @entity392 , which was indicated by a @entity1032 Inventory (THI) score >58%, received a Nucleus   CI in their deaf ear. The study design includes repeated within-subject measures on hearing, @entity392 , @entity7804 and quality of life up to 12 months after initial CI fitting. In addition to @entity393 and @entity392 , all @entity1 suffered from @entity7804 . Most @entity1 had a @entity2459 and received a CI within 2 years after their @entity393 . Preliminary 6-month, post-CI activation data of 13 subjects showed that the majority of @entity1 perceived a subjective benefit from CI treatment, which was assessed using the THI, a Visual Analogue Scale of @entity392 loudness/annoyance and the Speech, Spatial and Qualities of Hearing Scale. Preliminary 12-month data of 7 subjects showed that most @entity1 also perceived a degree of relief from their @entity7804 . One @entity1 showed no improvements in any of the applied scales, which could be explained by partial insertion of the electrode due to obstruction of the cochlea by @entity8719 . In conclusion, CI can successfully be used in the treatment of @entity393 @entity1 with accompanying severe @entity392 and @entity7804 . Implantation resulted in hearing benefits and a durable relief from @entity392 and @entity7804 in the majority of @entity1 . These findings support the hypothesis that pathophysiological mechanisms after peripheral @entity1274 are at least partly reversible when hearing is restored with a CI.    2015 S. Karger AG, Basel.

title: Cochlear Implants as a Treatment Option for Unilateral Hearing Loss, Severe XXXX and @entity7804 .

entities_list: @entity7804 :: ('MESH:D012001', 'Disease') :: ['hyperacusis']

entities_list: @entity1032 :: ('MESH:D008607', 'Disease') :: ['Tinnitus Handicap']

entities_list: @entity8719 :: ('MESH:D010040', 'Disease') :: ['otosclerosis']

entities_list: @entity392 :: ('MESH:D014012', 'Disease') :: ['tinnitus', 'Tinnitus']

entities_list: @entity1274 :: ('MESH:D006319', 'Disease') :: ['sensorineural hearing loss']

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['hearing loss', 'UHL', 'unilateral hearing loss']

entities_list: @entity2459 :: ('MESH:D003639', 'Disease') :: ['sudden hearing loss']

answer: @entity392 :: (MESH:D014012,Disease) :: ['Tinnitus']


abstract: UNASSIGNED: @entity392 is an incapacitating condition commonly affecting cochlear implant (CI) candidates. The aim of this clinical study is to assess the long-term effects of CI treatment in @entity1 with severe-to-profound, sensorineural, @entity393 ( @entity393 ) and incapacitating @entity392 . We performed a prospective Cochlear    company-sponsored multicentre study in five Spanish centres. Sixteen @entity1 with @entity393 and incapacitating @entity392 , which was indicated by a @entity1032 Inventory (THI) score >58%, received a Nucleus   CI in their deaf ear. The study design includes repeated within-subject measures on hearing, @entity392 , @entity7804 and quality of life up to 12 months after initial CI fitting. In addition to @entity393 and @entity392 , all @entity1 suffered from @entity7804 . Most @entity1 had a @entity2459 and received a CI within 2 years after their @entity393 . Preliminary 6-month, post-CI activation data of 13 subjects showed that the majority of @entity1 perceived a subjective benefit from CI treatment, which was assessed using the THI, a Visual Analogue Scale of @entity392 loudness/annoyance and the Speech, Spatial and Qualities of Hearing Scale. Preliminary 12-month data of 7 subjects showed that most @entity1 also perceived a degree of relief from their @entity7804 . One @entity1 showed no improvements in any of the applied scales, which could be explained by partial insertion of the electrode due to obstruction of the cochlea by @entity8719 . In conclusion, CI can successfully be used in the treatment of @entity393 @entity1 with accompanying severe @entity392 and @entity7804 . Implantation resulted in hearing benefits and a durable relief from @entity392 and @entity7804 in the majority of @entity1 . These findings support the hypothesis that pathophysiological mechanisms after peripheral @entity1274 are at least partly reversible when hearing is restored with a CI.    2015 S. Karger AG, Basel.

title: Cochlear Implants as a Treatment Option for Unilateral Hearing Loss, Severe @entity392 and XXXX .

answer: @entity7804 :: (MESH:D012001,Disease) :: ['Hyperacusis']


abstract: AIM: To evaluate the technical success and mid-term outcomes following transcatheter  embolisation  of type 1a endoleak after Nellix endovascular @entity439 sealing (EVAS). MATERIALS AND METHODS: Seven @entity1 (5 @entity1 ; mean age 83; range 79-90) underwent transcatheter embolisation between July 2013 and August 2014. The average time from EVAS to embolisation was 136  days (range 6-301) and from endoleak diagnosis to embolisation was 20  days (range 2-50). Embolisation  was performed with coils and Onyx in six cases and Onyx only in one case. Technical success, imaging and clinical outcomes of embolisation were reviewed. Technical success was defined as elimination of the endoleak on completion angiography and first imaging follow-up. Clinical success was defined as unchanged or decreased @entity439 sac size on subsequent follow-up (average 8  months; range 103-471  days). RESULTS: All cases were technically successful. One @entity1 required a second endovascular procedure following Onyx reflux into the Nellix endograft and another @entity1 required surgical closure of a brachial puncture site. All @entity1 are endoleak free with stable sac size on the latest available follow-up imaging. CONCLUSION: If a type 1 endoleak occurs after EVAS, embolisation using Onyx with or without coils is feasible and effective with high technical success and freedom from endoleak recurrence at mid-term follow-up.

title: Transcatheter Embolisation of Proximal Type 1 Endoleaks Following Endovascular XXXX (EVAS) Using the Nellix Device: Technique and Outcomes.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'men']

entities_list: @entity439 :: ('MESH:D000783', 'Disease') :: ['aneurysm']

answer: @entity439 :: (MESH:D000783,Disease) :: ['Aneurysm Sealing']


abstract: OBJECTIVE: To evaluate the prognostic factors affecting survival in @entity1721 ( @entity1721 ) @entity1 with pathologic T0 (ypT0) underwent preoperative radiotherapy. @entity1 AND METHODS: Two hundred and ninety-six @entity1 with @entity1721 who had received preoperative radiotherapy from 1980 to 2007 were retrospectively analyzed. One hundred @entity1 were ypT0 after preoperative radiotherapy. Univariate and multivariate analyses were performed to evaluate the predictive impact of residual lymph node status on @entity1349 ( @entity1349 ) and progression-free survival (PFS). RESULTS: Among the originally analyzed 296 @entity1 , 100 (33.7  %) @entity1 had ypT0, including 78 @entity1 (78  %) with ypT0N0, and 22 @entity1 (22  %) with ypT0N1. The 5-year @entity1349 of the total @entity1 was 42.4  %. @entity1 with ypT0N0 have significant improved 5-year @entity1349 and PFS than ypT0N1 @entity1 ( @entity1349 : 50.7  % vs 13.6  %, P   =   0.004; PFS: 49.6  % vs 13.6  %, P   =   0.003). In multivariate analysis, residual lymph node status was also an independent prognostic factors for @entity1349 (HR: 0.406, 95  % CI: 0.240-0.686, P   =   0.001) and PFS (HR: 0.427, 95  % CI: 0.248-0.734, P   =   0.002). CONCLUSION: Our results indicate that @entity1 with ypT0N0 after preoperative radiotherapy had significantly better @entity1349 and PFS than @entity1 with ypT0N1 in @entity1721 . Residual nodal metastasis of @entity1721 @entity1 with pathological complete response of the @entity5 after neoadjuvant radiotherapy does influence prognosis.

title: Residual lymph node status is an independent prognostic factor in XXXX with pathologic T0 after preoperative radiotherapy.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients', 'PATIENTS']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['primary tumor']

entities_list: @entity1721 :: ('MESH:C562729', 'Disease') :: ['ESCC', 'esophageal squamous cell Carcinoma']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

answer: @entity1721 :: (MESH:C562729,Disease) :: ['esophageal squamous cell Carcinoma']


abstract: OBJECTIVES: To evaluate the utility of @entity419 PET in re-staging and response assessment of @entity1 who underwent definitive treatment for @entity3852 ( @entity3852 ). METHODS AND MATERIALS: A retrospective review of @entity1 undergoing @entity8984 -FDG PET imaging for @entity3852 between January 1997 and October 2010 at the Peter MacCallum Cancer Centre with follow-up until February 2015 was performed. Data analysis was performed on @entity1 who were treated definitively and had post treatment PET imaging performed either as a re-staging scan for ongoing monitoring, suspicion of recurrence or assessment for suitability of salvage treatment or for response assessment within 1-6 months of treatment. Management plans were recorded prospectively prior to @entity419 PET imaging and compared to post imaging management to assess impact of the study as per our previously defined categories: "high" if the primary treatment modality or intent was changed; "medium" if the radiotherapy technique or dose was altered. In total, 62 @entity1 were included in the analysis. Thirty-six @entity1 had 53 restaging scans and 37 @entity1 had a response assessment scan. The median follow up of @entity1 in the re-staging group was 5.3 years (95% CI [4.6-9.4]), while it was 5.7 years (95% CI [4.3-10.8]) in the response assessment group. RESULTS: Re-staging @entity419 PET scans had a high impact in 24 of 53 cases (45%) and a medium impact in 6 of 53 cases (11%). In the response assessment group, 24 of 37 @entity1 had a complete metabolic response (CMR). @entity1 without a CMR had a 15% 1-year overall survival (95% CI 0.04-0.55). Those with a CMR had an 88% 2-year overall survival (95% CI 0.75-1.00) and a 68% 5-year overall survival (95% CI 0.49-0.95). Presence of a CMR (p<0.001) and nodal involvement (P = 0.016) were statistically significant prognostic factors for overall survival. CONCLUSION: @entity419 PET imaging had a high impact on restaging following definitive treatment in @entity1 with @entity3852 . Metabolic response was significantly associated with overall survival. @entity419 PET may play an important role in ongoing post treatment management of @entity3852 .

title: 15-year Experience of 18F-FDG PET Imaging in Response Assessment and Re-staging after Definitive XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity3852 :: ('MESH:D015266', 'Disease') :: ['Merkel cell carcinoma', 'MCC']

answer: @entity3852 :: (MESH:D015266,Disease) :: ['Treatment of Merkel Cell Carcinoma']


abstract: UNASSIGNED: Study Design Randomized controlled trial. Objectives To determine if thoracic spinal manipulative therapy (SMT) alters thoracic kinematics, thoracic excursion, and scapular kinematics compared to a sham-SMT in @entity1 with @entity158 , and also to compare changes in @entity1 -reported outcomes between treatment groups. Background Prior studies indicate that thoracic SMT can improve @entity158 in individuals with @entity158 . However, the mechanisms underlying these benefits are not well understood. Methods @entity1 with @entity5818 (n=52) were randomly assigned to receive a single session of thoracic SMT or sham-SMT. @entity1514 and scapular kinematics during active arm elevation and overall thoracic excursion were measured before and after the intervention. @entity1 -reported outcomes measured were: @entity158 ( @entity158 rating scale [NPRS]), function (Pennsylvania Shoulder Score [Penn]), and global rating of change (GROC). Results There were no significant differences between groups in changes post-intervention for thoracic kinematics or excursion, shoulder kinematics, or @entity1 -reported outcomes (P>.05). Both groups showed an increase in scapular internal rotation during arm raising (mean of 0.9  , 95% CI [0.3  , 1.6  ], P=.003) and lowering (0.8  , 95% CI [0.0  , 1.5  ], P=.041), as well as improved NPRS (1.2 points, 95% CI [0.3, 1.8], P<.001) and Penn (9.1 points, 95% CI [6.5, 11.7], P<.001) scores. Conclusion @entity1514 spine extension and excursion did not change significantly following thoracic SMT. There were small, but likely not clinically meaningful changes in scapular internal rotation in both groups. @entity1 -reported @entity158 and function improved in both groups, however there were no significant differences in the changes between the SMT and the sham-SMT groups. Overall, @entity1 -reported outcomes improved in both groups without meaningful changes to thoracic or scapular motion. Level of Evidence Therapy, level 1b-. J Orthop Sports Phys Ther, Epub 21 May 2015. doi:10.2519/jospt.2015.5647.

title: @entity1514 Spine Manipulation in Individuals With @entity5818 Does Not Immediately Alter @entity1514 Spine Kinematics, XXXX Excursion, or Scapular Kinematics: A Randomized Controlled Trial.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient', 'Participants', 'Patient']

entities_list: @entity5818 :: ('MESH:D019534', 'Disease') :: ['shoulder impingement symptoms']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['numeric pain', 'pain and disability', 'subacromial pain syndrome', 'pain']

answer: @entity1514 :: (MESH:D013896,Disease) :: ['Thoracic']


abstract: UNASSIGNED: Study Design Randomized controlled trial. Objectives To determine if thoracic spinal manipulative therapy (SMT) alters thoracic kinematics, thoracic excursion, and scapular kinematics compared to a sham-SMT in @entity1 with @entity158 , and also to compare changes in @entity1 -reported outcomes between treatment groups. Background Prior studies indicate that thoracic SMT can improve @entity158 in individuals with @entity158 . However, the mechanisms underlying these benefits are not well understood. Methods @entity1 with @entity5818 (n=52) were randomly assigned to receive a single session of thoracic SMT or sham-SMT. @entity1514 and scapular kinematics during active arm elevation and overall thoracic excursion were measured before and after the intervention. @entity1 -reported outcomes measured were: @entity158 ( @entity158 rating scale [NPRS]), function (Pennsylvania Shoulder Score [Penn]), and global rating of change (GROC). Results There were no significant differences between groups in changes post-intervention for thoracic kinematics or excursion, shoulder kinematics, or @entity1 -reported outcomes (P>.05). Both groups showed an increase in scapular internal rotation during arm raising (mean of 0.9  , 95% CI [0.3  , 1.6  ], P=.003) and lowering (0.8  , 95% CI [0.0  , 1.5  ], P=.041), as well as improved NPRS (1.2 points, 95% CI [0.3, 1.8], P<.001) and Penn (9.1 points, 95% CI [6.5, 11.7], P<.001) scores. Conclusion @entity1514 spine extension and excursion did not change significantly following thoracic SMT. There were small, but likely not clinically meaningful changes in scapular internal rotation in both groups. @entity1 -reported @entity158 and function improved in both groups, however there were no significant differences in the changes between the SMT and the sham-SMT groups. Overall, @entity1 -reported outcomes improved in both groups without meaningful changes to thoracic or scapular motion. Level of Evidence Therapy, level 1b-. J Orthop Sports Phys Ther, Epub 21 May 2015. doi:10.2519/jospt.2015.5647.

title: XXXX Spine Manipulation in Individuals With @entity5818 Does Not Immediately Alter @entity1514 Spine Kinematics, @entity1514 Excursion, or Scapular Kinematics: A Randomized Controlled Trial.

answer: @entity1514 :: (MESH:D013896,Disease) :: ['Thoracic']


abstract: UNASSIGNED: Study Design Randomized controlled trial. Objectives To determine if thoracic spinal manipulative therapy (SMT) alters thoracic kinematics, thoracic excursion, and scapular kinematics compared to a sham-SMT in @entity1 with @entity158 , and also to compare changes in @entity1 -reported outcomes between treatment groups. Background Prior studies indicate that thoracic SMT can improve @entity158 in individuals with @entity158 . However, the mechanisms underlying these benefits are not well understood. Methods @entity1 with @entity5818 (n=52) were randomly assigned to receive a single session of thoracic SMT or sham-SMT. @entity1514 and scapular kinematics during active arm elevation and overall thoracic excursion were measured before and after the intervention. @entity1 -reported outcomes measured were: @entity158 ( @entity158 rating scale [NPRS]), function (Pennsylvania Shoulder Score [Penn]), and global rating of change (GROC). Results There were no significant differences between groups in changes post-intervention for thoracic kinematics or excursion, shoulder kinematics, or @entity1 -reported outcomes (P>.05). Both groups showed an increase in scapular internal rotation during arm raising (mean of 0.9  , 95% CI [0.3  , 1.6  ], P=.003) and lowering (0.8  , 95% CI [0.0  , 1.5  ], P=.041), as well as improved NPRS (1.2 points, 95% CI [0.3, 1.8], P<.001) and Penn (9.1 points, 95% CI [6.5, 11.7], P<.001) scores. Conclusion @entity1514 spine extension and excursion did not change significantly following thoracic SMT. There were small, but likely not clinically meaningful changes in scapular internal rotation in both groups. @entity1 -reported @entity158 and function improved in both groups, however there were no significant differences in the changes between the SMT and the sham-SMT groups. Overall, @entity1 -reported outcomes improved in both groups without meaningful changes to thoracic or scapular motion. Level of Evidence Therapy, level 1b-. J Orthop Sports Phys Ther, Epub 21 May 2015. doi:10.2519/jospt.2015.5647.

title: @entity1514 Spine Manipulation in Individuals With @entity5818 Does Not Immediately Alter XXXX Spine Kinematics, @entity1514 Excursion, or Scapular Kinematics: A Randomized Controlled Trial.

answer: @entity1514 :: (MESH:D013896,Disease) :: ['Thoracic']


abstract: UNASSIGNED: Study Design Randomized controlled trial. Objectives To determine if thoracic spinal manipulative therapy (SMT) alters thoracic kinematics, thoracic excursion, and scapular kinematics compared to a sham-SMT in @entity1 with @entity158 , and also to compare changes in @entity1 -reported outcomes between treatment groups. Background Prior studies indicate that thoracic SMT can improve @entity158 in individuals with @entity158 . However, the mechanisms underlying these benefits are not well understood. Methods @entity1 with @entity5818 (n=52) were randomly assigned to receive a single session of thoracic SMT or sham-SMT. @entity1514 and scapular kinematics during active arm elevation and overall thoracic excursion were measured before and after the intervention. @entity1 -reported outcomes measured were: @entity158 ( @entity158 rating scale [NPRS]), function (Pennsylvania Shoulder Score [Penn]), and global rating of change (GROC). Results There were no significant differences between groups in changes post-intervention for thoracic kinematics or excursion, shoulder kinematics, or @entity1 -reported outcomes (P>.05). Both groups showed an increase in scapular internal rotation during arm raising (mean of 0.9  , 95% CI [0.3  , 1.6  ], P=.003) and lowering (0.8  , 95% CI [0.0  , 1.5  ], P=.041), as well as improved NPRS (1.2 points, 95% CI [0.3, 1.8], P<.001) and Penn (9.1 points, 95% CI [6.5, 11.7], P<.001) scores. Conclusion @entity1514 spine extension and excursion did not change significantly following thoracic SMT. There were small, but likely not clinically meaningful changes in scapular internal rotation in both groups. @entity1 -reported @entity158 and function improved in both groups, however there were no significant differences in the changes between the SMT and the sham-SMT groups. Overall, @entity1 -reported outcomes improved in both groups without meaningful changes to thoracic or scapular motion. Level of Evidence Therapy, level 1b-. J Orthop Sports Phys Ther, Epub 21 May 2015. doi:10.2519/jospt.2015.5647.

title: @entity1514 Spine Manipulation in Individuals With XXXX Does Not Immediately Alter @entity1514 Spine Kinematics, @entity1514 Excursion, or Scapular Kinematics: A Randomized Controlled Trial.

answer: @entity5818 :: (MESH:D019534,Disease) :: ['Subacromial Impingement Syndrome']


abstract: Measurements of serum @entity3745 (hTg) were performed using a specific radioimmunoassay. Sera with detectable anti- @entity3745 (anti-Tg) antibody titers (> or = 1:10) as assessed by passive hemagglutination were discarded. Assays were carried out under conditions in which anti-Tg titers less than 1:10 produced no interference. The assay sensitivity was 1.25 ng/ml and the mean +/- SE concentration of serum hTg in 58 control subjects was 9.5 +/- 0.9 ng/ml (range < 1.25-27 ng/ml). A slight but significant (p < 0.025) increase in the mean hTg level was observed in 12 pregnant @entity1 at delivery (25.7 +/- 5.2 ng/ml). Moderate to marked elevations of serum hTg were observed in @entity1 with @entity5651 (61.4 +/- 15 ng/ml; n = 23), @entity4941 (138 +/- 67 ng/ml; n = 5), toxic @entity652 (129 +/- 47 ng/ml; n = 13), untreated (424 +/- 101 ng/ml; n = 35) or treated (328 +/- 222 ng/ml; n = 14) toxic @entity5651 . 88 @entity1 with @entity259 and 10 with @entity5 were studied. The mean level of serum hTg was increased in untreated @entity259 (89.5 +/- 19 ng/ml; n = 13) but not in undifferentiated (10 +/- 2.9 ng/ml; n = 6) or medullary (0.8 +/- 0.2 ng/ml; = 3) @entity189 . In treated @entity259 the mean hTg levels were normal (8.2 +/- 0.2 ng/ml) in @entity1 (n = 24) with no evidence of either a thyroid residue or metastatic disease, moderately increased (56.6 +/- 16 ng/ml) in @entity1 (n = 27) with residual thyroid tissue, markedly elevated in @entity1 with lymph node metastases (199 +/- 50 ng/ml; n = 5) and extremely elevated in those with bone (4004 +/- 982 ng/ml; n = 8) or lung (2520 +/- 620 ng/ml; n = 5) metastases. There was no significant difference in serum hTg between functioning (n = 23) and nonfunctioning (n = 5) metastases as assessed by 131I whole body scan. A slight but significant (p < 0.0005) increase in the mean concentration of hTg was observed in @entity5 (21.7 +/- 4.5 ng/ml; n = 10). Serial measurements showed a transient increase of serum hTg after 131I therapy of @entity259 , toxic @entity5651 or toxic @entity652 , with peak values usually occurring within the first three days. A fall of serum hTg after administration of suppressive doses of thyroid hormone to @entity1 with @entity5651 and a rise after discontinuation of thyroid suppressive therapy in @entity1 with metastatic @entity259 was observed.(ABSTRACT TRUNCATED AT 400 WORDS)

title: Serum @entity3745 in XXXX and other thyroid disorders.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patients']

entities_list: @entity4941 :: ('MESH:D013968', 'Disease') :: ['subacute thyroiditis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['nonthyroidal malignancies']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma']

entities_list: @entity5651 :: ('MESH:D006042', 'Disease') :: ['diffuse goiter', 'nontoxic goiter']

entities_list: @entity259 :: ('MESH:D013964', 'Disease') :: ['thyroid carcinoma', 'differentiated thyroid carcinoma']

answer: @entity259 :: (MESH:D013964,Disease) :: ['thyroid carcinoma']


abstract: Measurements of serum @entity3745 (hTg) were performed using a specific radioimmunoassay. Sera with detectable anti- @entity3745 (anti-Tg) antibody titers (> or = 1:10) as assessed by passive hemagglutination were discarded. Assays were carried out under conditions in which anti-Tg titers less than 1:10 produced no interference. The assay sensitivity was 1.25 ng/ml and the mean +/- SE concentration of serum hTg in 58 control subjects was 9.5 +/- 0.9 ng/ml (range < 1.25-27 ng/ml). A slight but significant (p < 0.025) increase in the mean hTg level was observed in 12 pregnant @entity1 at delivery (25.7 +/- 5.2 ng/ml). Moderate to marked elevations of serum hTg were observed in @entity1 with @entity5651 (61.4 +/- 15 ng/ml; n = 23), @entity4941 (138 +/- 67 ng/ml; n = 5), toxic @entity652 (129 +/- 47 ng/ml; n = 13), untreated (424 +/- 101 ng/ml; n = 35) or treated (328 +/- 222 ng/ml; n = 14) toxic @entity5651 . 88 @entity1 with @entity259 and 10 with @entity5 were studied. The mean level of serum hTg was increased in untreated @entity259 (89.5 +/- 19 ng/ml; n = 13) but not in undifferentiated (10 +/- 2.9 ng/ml; n = 6) or medullary (0.8 +/- 0.2 ng/ml; = 3) @entity189 . In treated @entity259 the mean hTg levels were normal (8.2 +/- 0.2 ng/ml) in @entity1 (n = 24) with no evidence of either a thyroid residue or metastatic disease, moderately increased (56.6 +/- 16 ng/ml) in @entity1 (n = 27) with residual thyroid tissue, markedly elevated in @entity1 with lymph node metastases (199 +/- 50 ng/ml; n = 5) and extremely elevated in those with bone (4004 +/- 982 ng/ml; n = 8) or lung (2520 +/- 620 ng/ml; n = 5) metastases. There was no significant difference in serum hTg between functioning (n = 23) and nonfunctioning (n = 5) metastases as assessed by 131I whole body scan. A slight but significant (p < 0.0005) increase in the mean concentration of hTg was observed in @entity5 (21.7 +/- 4.5 ng/ml; n = 10). Serial measurements showed a transient increase of serum hTg after 131I therapy of @entity259 , toxic @entity5651 or toxic @entity652 , with peak values usually occurring within the first three days. A fall of serum hTg after administration of suppressive doses of thyroid hormone to @entity1 with @entity5651 and a rise after discontinuation of thyroid suppressive therapy in @entity1 with metastatic @entity259 was observed.(ABSTRACT TRUNCATED AT 400 WORDS)

title: Serum XXXX in @entity259 and other thyroid disorders.

answer: @entity3745 :: (7038,Gene) :: ['thyroglobulin']


abstract: QUESTIONS UNDER STUDY: In this work we wanted to evaluate the effect of intra-articular injection (IAI) at the knee joint of 1 ml of Diprospan on the @entity2339 . METHODS: Consecutive @entity1 attending the rheumatology or orthopaedic clinic with osteoarthritic knee @entity158 not responding satisfactorily to medical and physical therapy were asked to participate in our study. After consent, @entity1 had ultrasound-guided IAI of 1 ml of Diprospan, containing 2 mg of betamethasone sodium phosphate and 5 mg of betamethasone dipropionate. Demographic, clinical, laboratory and radiographic variables were documented. Just prior to the knee injection and 1, 2, 4 and 6 weeks later, @entity1 had a 1-  g @entity4545 (ACTH) stimulation test. @entity1887 ( @entity1887 ) was defined as a poststimulation (30 minutes after ACTH injection) serum cortisol level of less than 18   g/dl (~500 nmol/l) and lack of a rise of >6   g/dl (~166 nmol/l) over the basal level in poststimulation serum cortisol. RESULTS: Twenty @entity1 completed the study. There were 3 male and 17 female @entity1 , with a mean age of 58.6    9.5 years. Six (30%) @entity1 had evidence of @entity1887 and in five of them it was seen at one time-point, mostly at week 2 after the IAI. In one @entity1 , @entity1887 was prolonged and observed from week 1 to week 4. CONCLUSIONS: IAI at the knee joint of 1 ml of Diprospan was associated with a transient high rate of @entity1887 .

title: The effect of intra-articular injection of Diprospan at the knee joint on the XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity4545 :: ('5443', 'Gene') :: ['adrenocorticotropic hormone']

entities_list: @entity1887 :: ('MESH:D000309', 'Disease') :: ['SAI', 'Secondary adrenal insufficiency']

entities_list: @entity2339 :: ('MESH:D007029', 'Disease') :: ['hypothalamic-pituitary-adrenal (HPA) axis']

answer: @entity2339 :: (MESH:D007029,Disease) :: ['hypothalamic-pituitary-adrenal axis']


abstract: OBJECTIVE: @entity2167 ( @entity2167 ) is a @entity395 with variable management strategies and prognosis. We aimed to analyze treatment modalities, prognostic factors and survival outcomes in @entity1 of @entity957 of EAC treated at our institution. METHODS: Forty-three @entity1 of @entity957 of EAC were analyzed for clinical presentation, stage, surgical procedures and radiotherapy (RT) modalities employed. Stell and McCormick staging system was used for staging of the @entity1 . Progression free survival (PFS) was estimated by the use of Kaplan-Meier product-limit method. Log rank test was used to assess the impact of prognostic variables on PFS. Multivariate analysis was performed using the Cox hazard regression model. p value of <0.05 was considered significant for all statistical analysis. RESULTS: Median age was 56 years (range: 12-84 years). Male to female ratio was 31:12. Stage was T1, T2 and T3 in 2, 17 and 18 @entity1 respectively. Sixteen @entity1 underwent surgery. Thirty-six @entity1 received RT (14 received definitive RT, 11 had post-operative RT and 11 had RT with palliative intent). Eight @entity1 (16%) received chemotherapy (5 received concurrent with RT, 2 had adjuvant and 1 had neo-adjuvant chemotherapy). Nine @entity1 (of 11 @entity1 ) achieved a @entity10911 achieved a partial response (PR) after surgery plus post-operative RT. Nine @entity1 and 5 @entity1 respectively achieved CR and PR after definitive RT (with or without concurrent chemotherapy). Of the 11 @entity1 who received palliative RT, 2 had very good objective response (>50%) and 7 @entity1 had PR to palliative RT. After a median follow-up of 16 months, median PFS for the entire cohort was 14 months. Two-year PFS rates were 85.7%, 46.9% and 0% for @entity1 treated with surgery and post-operative RT, definitive RT and palliative RT respectively. On univariate analysis, higher stage (p=0.05) and @entity2103 at presentation (p=0.0008) were significant predictors of inferior PFS. CONCLUSION: @entity1 with @entity2167 present mostly in advanced stage at our centre. Combined higher stage (T3) and @entity2103 at presentation portend poorer outcome. Combined modality treatment with surgery and radiotherapy should be advocated and palliative RT remains a reasonable treatment option in @entity1 with advanced incurable disease.

title: Treatment of squamous cell XXXX : A tertiary cancer centre experience.

entities_list: @entity10911 :: ('1380', 'Gene') :: ['complete response (CR) and 2']

entities_list: @entity2167 :: ('MESH:D006311', 'Disease') :: ['carcinoma of EAC', 'EAC', 'Carcinoma of external auditory canal']

entities_list: @entity957 :: ('MESH:D002294', 'Disease') :: ['squamous cell carcinoma']

entities_list: @entity2103 :: ('MESH:D005155', 'Disease') :: ['facial nerve palsy']

entities_list: @entity395 :: ('MESH:D035583', 'Disease') :: ['rare disease']

answer: @entity2167 :: (MESH:D006311,Disease) :: ['carcinoma of external auditory canal']


abstract: The aim of this study was to correlate endoscopic, radiological and pathological observations in 30 @entity1 with @entity30 , with involvement of the stomach and/or duodenum. The incidence of gastroduodenal involvement in our @entity1 with @entity30 is about 3%. 22 of the 30 @entity1 had intrinsic lesions of the stomach and/or duodenum; in 8 @entity1 the lesions seemed to be produced by involvement from contiguous diseased bowel. Radiological studies and endoscopy of the gastroduodenal region are complementary. @entity33 . Other features, for example a diminished expansion and the presence of contiguity lesions, are better demonstrated by barium meal. The @entity3137 found at endoscopy are heterogenous, but irregularly-shaped @entity1066 and erosions in a disrupted mucosal pattern are typical for gastroduodenal @entity30 . Pathological examination of endoscopic "forceps"-biopsies permitted a conclusive diagnosis based on the presence of @entity738 , in 15/22 (68%) of the cases with @entity66 . This observation indicates that simple forceps biopsy is a very useful diagnostic tool. Involvement of the first part of the duodenum in @entity30 was complicated by a @entity3116 in two @entity1 .

title: XXXX of the stomach and duodenum: A clinical study with emphasis on the value of endoscopy and endoscopic biopsies.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['intrinsic gastroduodenal disease']

entities_list: @entity738 :: ('MESH:D006099', 'Disease') :: ['granulomas']

entities_list: @entity33 :: ('MESH:D052016', 'Disease') :: ['Endoscopy allows better visualisation of mucosal defects']

entities_list: @entity3116 :: ('MESH:D001658', 'Disease') :: ['biliary fistula']

entities_list: @entity30 :: ('MESH:D003424', 'Disease') :: ["Crohn's disease"]

entities_list: @entity3137 :: ('MESH:D009059', 'Disease') :: ['mucosal lesions']

answer: @entity30 :: (MESH:D003424,Disease) :: ['Crohn's disease']


abstract: UNASSIGNED: Animal behavior can have profound effects on pathogen transmission and disease incidence. We studied the questing (= host-seeking) behavior of @entity3966 ( @entity3966 ) nymphs, which are the primary vectors of @entity3001 in the eastern United States. @entity3001 is common in northern but not in southern regions, and prior ecological studies have found that standard methods used to collect host-seeking nymphs in northern regions are unsuccessful in the south. This led us to hypothesize that there are behavior differences between northern and southern nymphs that alter how readily they are collected, and how likely they are to transmit the etiological agent of @entity3001 to @entity1 . To examine this question, we compared the questing behavior of @entity3966 nymphs originating from one northern ( @entity3001 endemic) and two southern (non-endemic) US regions at field sites in Wisconsin, Rhode Island, Tennessee, and Florida. Laboratory-raised uninfected nymphs were monitored in circular 0.2 m2 arenas containing wooden dowels (mimicking stems of understory vegetation) for 10 (2011) and 19 (2012) weeks. The probability of observing nymphs questing on these stems (2011), and on stems, on top of leaf litter, and on arena walls (2012) was much greater for northern than for southern origin ticks in both years and at all field sites (19.5 times greater in 2011; 3.6-11.6 times greater in 2012). Our findings suggest that southern origin @entity3966 nymphs rarely emerge from the leaf litter, and consequently are unlikely to contact passing @entity1 . We propose that this difference in questing behavior accounts for observed geographic differences in the efficacy of the standard sampling techniques used to collect questing nymphs. These findings also support our hypothesis that very low @entity3001 incidence in southern states is, in part, a consequence of the type of host-seeking behavior exhibited by southern populations of the key @entity3001 vector.

title: Different Populations of XXXX Nymphs Exhibit Differences in Questing Behavior That Have Implications for @entity1 Lyme Disease Risk.

entities_list: @entity3001 :: ('MESH:D008193', 'Disease') :: ['Lyme disease']

entities_list: @entity3966 :: ('6945', 'Species') :: ['I. scapularis', 'blacklegged tick', 'Ixodes scapularis']

answer: @entity3966 :: (6945,Species) :: ['Blacklegged Tick']


abstract: UNASSIGNED: Animal behavior can have profound effects on pathogen transmission and disease incidence. We studied the questing (= host-seeking) behavior of @entity3966 ( @entity3966 ) nymphs, which are the primary vectors of @entity3001 in the eastern United States. @entity3001 is common in northern but not in southern regions, and prior ecological studies have found that standard methods used to collect host-seeking nymphs in northern regions are unsuccessful in the south. This led us to hypothesize that there are behavior differences between northern and southern nymphs that alter how readily they are collected, and how likely they are to transmit the etiological agent of @entity3001 to @entity1 . To examine this question, we compared the questing behavior of @entity3966 nymphs originating from one northern ( @entity3001 endemic) and two southern (non-endemic) US regions at field sites in Wisconsin, Rhode Island, Tennessee, and Florida. Laboratory-raised uninfected nymphs were monitored in circular 0.2 m2 arenas containing wooden dowels (mimicking stems of understory vegetation) for 10 (2011) and 19 (2012) weeks. The probability of observing nymphs questing on these stems (2011), and on stems, on top of leaf litter, and on arena walls (2012) was much greater for northern than for southern origin ticks in both years and at all field sites (19.5 times greater in 2011; 3.6-11.6 times greater in 2012). Our findings suggest that southern origin @entity3966 nymphs rarely emerge from the leaf litter, and consequently are unlikely to contact passing @entity1 . We propose that this difference in questing behavior accounts for observed geographic differences in the efficacy of the standard sampling techniques used to collect questing nymphs. These findings also support our hypothesis that very low @entity3001 incidence in southern states is, in part, a consequence of the type of host-seeking behavior exhibited by southern populations of the key @entity3001 vector.

title: Different Populations of @entity3966 Nymphs Exhibit Differences in Questing Behavior That Have Implications for XXXX Lyme Disease Risk.

answer: @entity1 :: (9606,Species) :: ['Human']


abstract: Herein, we report clinical, radiological, and follow-up results of seven cases of @entity705 and highlight the importance of rare and unusual properties of unusual locations of @entity705 . Seven @entity1 with @entity705 were treated in our institution (Antalya Memorial Hospital) between the period of February 2009 and March 2014 were reported. The @entity1 were classified according to the localization, symptomatology, and the presence of neurovascular involvement or organ compression. The results were discussed with the existing literature data. Five of our @entity1 had unusual symptomatology. Surgical excision was performed on six of seven @entity1 . One @entity1 was followed with scheduled outpatient visits alone. Our clinical follow-up results were good to excellent. In our case series, one @entity1 with clavicular involvement had impaired shoulder mechanic which resulted in @entity158 , while another with pubic ramus involvement had obstructive urination symptoms and @entity3833 . One @entity1 with scapular involvement had snapping scapula symptoms, while two @entity1 with fibular head involvement had @entity2850 and @entity2850 symptoms in each. One @entity1 with ischial ramus involvement had sciatica, whereas another with first rib involvement had radiological evidences for subclavian @entity2850 without any symptom. Based our experience, the flat bones which are usually ossified by intramembranous type of ossification during the fetal period (including the scapula, ilium, pubic ramus, ischium ramus, ribs and clavicle) are much less commonly affected and often have unusual symptoms. The @entity705 originating from the fibular head may seem innocent to an orthopedic surgeon. However, an orthopedic surgeon should be alert to tibiofibular @entity2850 in this @entity1 population.

title: XXXX originating from unusual locations complicating orthopedic discipline: case series.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity705 :: ('MESH:D015831', 'Disease') :: ['osteochondromas', 'extraordinary located osteochondromas']

entities_list: @entity2850 :: ('MESH:D009408', 'Disease') :: ['peroneal nerve compression', 'artery compression due to osteochondroma', 'tibial nerve compression', 'synostosis and nerve compression']

entities_list: @entity158 :: ('MESH:D010146', 'Disease') :: ['painful shoulder']

answer: @entity705 :: (MESH:D015831,Disease) :: ['Osteochondromas']


abstract: Microenvironment plays an important role in epithelial-mesenchymal transition (EMT) and @entity3308 of cells in @entity157 ( @entity157 ). @entity5960 ( @entity5960 ) is known as a @entity5 @entity3308 marker of @entity157 . To investigate the relationship between microenvironment and @entity3308 , we performed an in  vitro co-culture assay. Four @entity157 cell lines (HepG2, Hep3B, @entity5959 and @entity9294 /PRF/5) were co-cultured with the TWNT-1 immortalized hepatic stellate cells (HSCs), which create a microenvironment with @entity157 . Cell proliferation ability was analyzed by flow cytometry (FCM) and @entity2454 ( @entity98 ) assay, while migration ability was assessed by a wound healing assay. Expression of @entity5960 was analyzed by immunoblotting and FCM. @entity157 cell lines were co-cultured with TWNT-1 treated with small interfering RNA (siRNA) for @entity2533 and @entity20107 ; we then analyzed proliferation, migration ability and protein expression using the methods described above. Proliferation ability was unchanged in @entity157 cell lines co-cultured with TWNT-1. Migration ability was increased in @entity157 cell lines (HepG2, Hep3B, @entity5959 and @entity9294 /PRF/5) directly (216.2  67.0, 61.0  22.0, 124.0  66.2 and 51.5  40.3%) and indirectly (102.5  22.0, 84.6  30.9, 86.1  25.7 and 73.9  29.7%) co-cultured with TWNT-1 compared with the @entity157 uni-culture. Immunoblot analysis revealed increased @entity5960 expression in the @entity157 cell lines co-cultured with TWNT-1. Flow cytometry revealed that the population of @entity5962 -/ @entity6076 + and @entity5960 -positive cells increased and accordingly, EMT and @entity3308 in the @entity157 cell line were activated. These results were similar in the directly and indirectly co-cultured samples, indicating that humoral factors were at play. Conversely, @entity157 cell lines co-cultured with siRNA  -treated TWNT-1 showed decreased migration ability, a decreased population of @entity5960 -positive and @entity5962 -/ @entity6076 + cells. Taken together, humoral factors secreted from TWNT-1 promote upregulation of @entity5960 and EMT in @entity96 cells.

title: Hepatic stellate cells promote upregulation of XXXX and epithelial-mesenchymal transition in @entity96 cells.

entities_list: @entity5960 :: ('4072', 'Gene') :: ['Epithelial cell adhesion molecule', 'EpCAM']

entities_list: @entity96 :: ('MESH:D008113', 'Disease') :: ['hepatic cancer']

entities_list: @entity2454 :: ('MESH:C022616', 'Chemical') :: ['3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide']

entities_list: @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'hepatocellular carcinoma']

answer: @entity5960 :: (4072,Gene) :: ['epithelial cell adhesion molecule']